Husband has acquired resistance to Tarceva after about 7 months. Searching clinical trials and discussing possible options. Wondered how a patient would determine if a trial geared toward T790 inhibitor or geared toward PIK3 inhibitor would be of greater value? Is a biopsy the only way to determine this or does having the EGFR mutation make him fair game for either trial. I realize these are trials and the information is limited, I just wondered from a professional perspective what the determining factors would be to place an EGFR patient in one trial over the other. We remain hopeful and grateful.
Thu, 12/13/2012 - 21:38#1
CO 1686 vs. BKM120 - 1251340